Camrelizumab
Camrelizumab is a therapeutic monoclonal antibody used in cancer immunotherapy.
Camrelizumab is a therapeutic monoclonal antibody used in cancer immunotherapy. It is a Programmed cell death 1 (PD-1) (PD-1) inhibitor, meaning it blocks the PD-1 immune checkpoint pathway that normally dampens T-cell activity. By inhibiting this checkpoint, camrelizumab can enhance antitumor immune responses and is therefore studied across multiple solid tumors, often in combination with other systemic therapies.
In recent biomedical research, camrelizumab has been investigated as both an adjuvant treatment after surgery and as part of combination regimens with agents such as apatinib, capecitabine, and oxaliplatin. These studies reflect its role as a checkpoint inhibitor in disease settings including hepatocellular carcinoma, gastric or gastro-oesophageal junction adenocarcinoma, metastatic clear cell renal cell carcinoma, and locoregionally advanced nasopharyngeal carcinoma.
Where the papers sit
9 papers from the last 6 months study camrelizumab directly · updated from PubMed 2 Nov 2026
Study type 7 clinical trials · 1 observational · 1 human data
Themes one subject
Those 9 are all about one subject.
-
Combination Immunotherapy in Solid Tumors
Checkpoint blockade is being paired with chemotherapy, radiotherapy, antiangiogenic therapy, or nimotuzumab across locally advanced and metastatic solid tumors. Apatinib recurs in maintenance and liver cancer regimens, while chemoradiotherapy is prominent in rectal, cervical, and small-cell lung cancer. Most evidence comes from phase II, single-arm studies assessing response, survival, and safety rather than randomized comparisons. The common direction is toward multimodal treatment, but the breadth of cancers and limited controlled evidence leave the best combinations and sequencing unresolved.
Papers
The 9 papers from the last 6 months that study camrelizumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Combination Immunotherapy in Solid Tumors (9)
- Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology · 25 Oct 2026 PMID 42927765
- Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial. Signal transduction and targeted therapy · 13 Oct 2026 PMID 42869886
- First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study. Lung cancer (Amsterdam, Netherlands) · 21 Sept 2026 PMID 42767923
- Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study. Journal for immunotherapy of cancer · 8 Sept 2026 PMID 42711069
- Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial. Clinical oncology (Royal College of Radiologists (Great Britain)) · 3 Aug 2026 PMID 42546669
- Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective clinical analysis. Clinics and research in hepatology and gastroenterology · 1 Jul 2026 PMID 42385878
- Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
- Cost-effectiveness of adjuvant therapy with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma: from the perspective of the Chinese healthcare system. Annals of medicine · 14 May 2026 PMID 42130296
- Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 13 May 2026 PMID 42127327
By study type
Clinical trials (7)
- Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology · 25 Oct 2026 PMID 42927765
- Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial. Signal transduction and targeted therapy · 13 Oct 2026 PMID 42869886
- First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study. Lung cancer (Amsterdam, Netherlands) · 21 Sept 2026 PMID 42767923
- Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study. Journal for immunotherapy of cancer · 8 Sept 2026 PMID 42711069
- Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial. Clinical oncology (Royal College of Radiologists (Great Britain)) · 3 Aug 2026 PMID 42546669
- Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
- Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 13 May 2026 PMID 42127327
Observational studies and case reports (1)
- Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective clinical analysis. Clinics and research in hepatology and gastroenterology · 1 Jul 2026 PMID 42385878
Human data, design not indexed (1)
- Cost-effectiveness of adjuvant therapy with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma: from the perspective of the Chinese healthcare system. Annals of medicine · 14 May 2026 PMID 42130296
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.